Physician profile
Ronan Lev
NPI 1871602573
$7,841.05
in general payments reported to CMS, 2019-2025
36 companies · $1,615 in 2025
The $1,615 reported for 2025 was more than what 75% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $984 · 2020: $704 · 2021: $750 · 2022: $1,733 · 2023: $1,196 · 2024: $859 · 2025: $1,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,669.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $2,310.17 | 2021-2025 | Urolift, Barrigel |
| Neotract INC. | $1,017.85 | 2019-2020 | |
| Boston Scientific Corporation | $515.56 | 2019-2025 | Spaceoar Vue System - 10ml |
| Astellas Pharma US INC | $467.53 | 2019-2024 | Myrbetriq |
| Sumitomo Pharma America, INC. | $390.20 | 2023-2025 | Gemtesa, Orgovyx |
| Ferring Pharmaceuticals INC. | $367.32 | 2024-2025 | Adstiladrin |
| Accord Healthcare, INC. | $338.42 | 2023-2024 | |
| Urogen Pharma, INC. | $308.10 | 2023-2025 | Jelmyto |
| Janssen Biotech, INC. | $267.67 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Myriad Genetic Laboratories, INC. | $262.28 | 2021-2023 | Prolaris |
| Procept Biorobotics Corporation | $243.20 | 2024-2025 | Aquabeam System |
| Cook Medical LLC | $172.61 | 2025 | Cook |
| Olympus America INC. | $162.61 | 2023-2025 | Itind System |
| Janssen Scientific Affairs, LLC | $124.98 | 2025 | Erleada |
| Laborie Medical Technologies Corp. | $69.17 | 2020-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $65.53 | 2021 | |
| Abbvie INC. | $62.69 | 2019-2024 | |
| Karl Storz Endoscopy-America | $62.50 | 2019 | |
| Telix Pharmaceuticals | $60.83 | 2024 | Illuccix |
| Progenics Pharmaceuticals, INC. | $60.04 | 2022-2024 | Pylarify |
| Antares Pharma, INC. | $54.30 | 2020-2023 | Tlando, Xyosted, Nocdurna |
| Myovant Sciences INC. | $48.61 | 2022 | |
| Tolmar, INC. | $46.17 | 2023 | |
| Merck Sharp & Dohme LLC | $45.84 | 2021-2023 | Welireg, Lynparza, Keytruda |
| Heron Therapeutics, INC. | $42.30 | 2022-2023 | Zynrelef |
| Blue Earth Diagnostics | $38.02 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.88 | 2024-2025 | |
| Medtronic, INC. | $33.71 | 2024 | Interstim |
| Mission Pharmacal Company | $32.71 | 2019 | |
| Pfizer INC. | $29.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.31 | 2025 | |
| Amgen INC. | $25.23 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.91 | 2019 | |
| Convatec INC. | $13.45 | 2019 | |
| Urovant Sciences INC | $12.32 | 2022 | |
| 180 Medical, INC. | $11.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronan Lev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.